- Home
- GWH vs MAIA Comparison
GWH vs MAIA Comparison
Compare GWH & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWH
- MAIA
- Stock Information
- Founded
- GWH 2011
- MAIA 2018
- Country
- GWH United States
- MAIA United States
- Employees
- GWH N/A
- MAIA N/A
- Industry
- GWH Industrial Machinery/Components
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- GWH Miscellaneous
- MAIA Health Care
- Exchange
- GWH Nasdaq
- MAIA Nasdaq
- Market Cap
- GWH 50.0M
- MAIA 44.9M
- IPO Year
- GWH N/A
- MAIA 2022
- Fundamental
- Price
- GWH $2.41
- MAIA $0.92
- Analyst Decision
- GWH Hold
- MAIA
- Analyst Count
- GWH 3
- MAIA 0
- Target Price
- GWH $2.67
- MAIA N/A
- AVG Volume (30 Days)
- GWH 896.4K
- MAIA 298.1K
- Earning Date
- GWH 11-13-2025
- MAIA 11-07-2025
- Dividend Yield
- GWH N/A
- MAIA N/A
- EPS Growth
- GWH N/A
- MAIA N/A
- EPS
- GWH N/A
- MAIA N/A
- Revenue
- GWH $6,021,000.00
- MAIA N/A
- Revenue This Year
- GWH $131.04
- MAIA N/A
- Revenue Next Year
- GWH $76.74
- MAIA N/A
- P/E Ratio
- GWH N/A
- MAIA N/A
- Revenue Growth
- GWH N/A
- MAIA N/A
- 52 Week Low
- GWH $0.76
- MAIA $0.87
- 52 Week High
- GWH $13.87
- MAIA $2.74
- Technical
- Relative Strength Index (RSI)
- GWH 38.28
- MAIA 31.20
- Support Level
- GWH $2.40
- MAIA $0.87
- Resistance Level
- GWH $2.77
- MAIA $1.09
- Average True Range (ATR)
- GWH 0.45
- MAIA 0.08
- MACD
- GWH -0.27
- MAIA -0.01
- Stochastic Oscillator
- GWH 8.37
- MAIA 15.07
About GWH ESS Tech Inc.
ESS Tech Inc is a long-duration energy storage company specializing in iron flow battery technology. The company design and produce long-duration batteries predominantly using earth-abundant materials.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.